top of page
national-cancer-institute-L7en7Lb-Ovc-unsplash.jpg

Navigates through the rapidly evolving oncology field

Services

Deal Evaluation and Due Diligence

Oncology has become the largest area of the pharmaceutical industry that nowadays mostly sources innovation from biotechs. Oncology is by far the most important area for M&A in life sciences — garnering $45 billion in 2020. Furthermore, in 2021 about half of the companies that listed on the NASDAQ were in oncology. Consequently, oncology is now also the most popular investment area. The accessibility of private and public funding is fueling the interest of scientists and entrepreneurs to valorize their inventions, leading to a surge in oncology start-ups being offered to investors. Oncopreneur can quickly filter out the winners in this competitive area, tapping into his 15 years of involvement in the oncology space as an entrepreneur and investor (having evaluated >1500 oncology deals).

​

Services that Oncopreneur provides are:

​

  • Help investors to mount the increasing amount of oncology dealflow, ranging from quick scans to deep support with due diligence, to understand which technologies provide a truly unique edge in rapidly changing treatment landscapes

  • Landscaping analysis of technology area's, targets and indications 

  • SWOT, Gap analysis, assessing deals for overall development ability

  • Source innovative technology in European hotspots of cancer research

  • Setup analytics framework to evaluate deals or portfolio performance

​

Corporate and R&D Strategy Development

In 2020, about one third of FDA approved drugs were oncology medicines, representing the lion-share of new drugs being admitted to the market. Most tumors have become highly segmented markets in which treatment regimens consist of a multitude of options oncologists can choose from.  The selection of treatment is based on assessment of health status, histological pathology, risk profile and genetic or molecular biomarkers. The rapidly changing treatment landscapes requires deep knowledge of the oncology field,  Oncopreneur's vision is that companies should start with the end goal in mind (product label) and work backwards to define the datapackages needed to transition the product through the phases of drug development. Oncopreneur has been tracking oncology deals since 2004 and thus knows the value inflection points that trigger venture investments or a pharma partnering deal. Oncopreneur has been part of task forces within Macrophage Pharma, Inthera Bioscience and Mimetas to develop R&D strategies, target-product profiles, fundraising strategies i.e.

​

Services that Oncopreneur provides are:

 

  • Strategic support to biotech executives in development or revision of a company's corporate strategy, taking into account competitive and market developments

  • (Re-)positioning technology proposition to tumor treatment lines, culminating in (business) target product profiles with definitions of thresholds that need to be achieved.

  • Identify killer applications for platform technologies

  • Full spectrum of competitive landscaping: similar type of MoA & standard of care & competitive agents for the target indication with  dissimilar MoA

  • Identifying indications for oncology products, by assessing the strength of the company's data and IP, clinical parameters, market sizes and needs, scientific and competitive developments

  • Assessment of datapackages for being ready for fundraising of partnering

  • Gap analysis as confirmatory check for follow-on venture financing

  • Refinement of fundraising and and partering narrative

​

​

​

​

NewCo Creation and Development

Investors increasingly invest in early-stage disruptive inventions originating from academia. Rather than committing to a full investment in a Newco, project-based financing over a period of 1-2 years can be a good strategy to prove or disprove a technology's potential. Oncopreneur has a trackrecord in progressing projects to Go/No Go decision points to continue further investments. Oncopreneur also supports investors in efficient NewCo creation and development, benefiting from its experience in NewCo creation and relevant network in the oncology field. Oncopreneur was involved in multiple NewCo creations, most notably as interim-CEO of Sapreme Technologies. He navigated Sapreme from initial incubation to professional biotech, establishing animal PoCs, IP portfolio and BD campaigns to pharma. Oncopreneur's global network consists of i.e. oncology BD teams within big pharma, pre-clinical and clinical CROs, institutional life sciences investors, academic innovators, medical KOLs and IP professionals.

​

Services that Oncopreneur has experience with:

​

  • Technology landscaping analysis to understand a technology's competitive edge 

  • Gap analysis to understand a technology's potential, limitations and pitfalls

  • Identify the best platform - tumor (treatment line) fits from the > 100 tumors and biomarker segmented subtypes that exist  (see "News" for more info on my approach)

  • Development of a business plan, R&D plan and budgets with inclusion of venture financing and pharma inflection points (see "News for more info on my thoughts here)

  • Develop pitchdeck, marketing strategy, fundraising and pharma partnering campaign

  • Lead fundraising campaigns to VCs and partnering discussions with pharma

  • Manage NewCo's R&D team or CRO-lead team executing killer PoC experiments

  • Provide oversight to establishment of NewCo's IP portfolio and IP strategy

  • Negotiate research and license collaborations with TTOs

  • HR matters: create corporate company culture, coordinate recruitment of team members

​

​

​

​

bottom of page